FOSIROL Powder (Fosfomycin trometamol)
Table of Content
Urinary tract infections (UTIs) are one of the most common bacterial infections. Acute uncomplicated cystitis is the most common type of UTI which occurs in healthy young women. Around 50% of women experience at least one episode of UTI at some point in their lifetime and recurrent UTI occur in about 20-40% of women.
Antibiotic therapy is the main stay of management for UTI. Since there is alarming increase in antimicrobial resistance particularly to broad-spectrum antibiotics such as fluoroquinolones and cephalosporins, it is essential to limit their use in uncomplicated infections.
Fosfomycin is a broad-spectrum bactericidal antibiotic. It is recommended by the European Association of Urology (EAU) and Infectious Disease Society of America (IDSA) guidelines as first-line antibiotic for empirical treatment of women with acute uncomplicated cystitis.
Fosfomycin has excellent in vitro activity against urinary E.coli isolates. Despite being in use for many years, fosfomycin continues to have a low resistance rates against E.coli. It has unique pharmacokinetic profile which makes it an ideal drug for single-dose therapy and it is the only antibacterial approved by US FDA. The clinical cure and bacteriological eradication was good with fosfomycin in the treatment of patients with acute uncomplicated cystitis and it was generally well tolerated. Advantage with single-dose therapy is that it improves patient compliance.
The recommended dosage of FOSIROL (fosfomycin trometamol) for women, 18 years of age and older, for uncomplicated urinary tract infection (acute cystitis) is one sachet of FOSIROL. It may be taken with or without food. FOSIROL should not be taken in its dry form. Always mix it with water before ingesting. FOSIROL should be taken orally. Pour the entire contents of a single-dose sachet of FOSIROL into a glass of water (90-120 ml) and stir to dissolve. Do not use hot water. FOSIROL should be taken immediately after dissolving in water.